



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
			Application Number	10/622205	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Filing Date	July 18, 2003	
			First Named Inventor	Subhashis Banerjee	
			Art Unit	1641	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	3	Attorney Docket Number	BPI-195

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
DB	A1	6,090,382	07/18/2000	Salfeld <i>et al.</i>	
DB	A2	6,258,562 B1	07/10/2001	Salfeld <i>et al.</i>	
DB	A3	6,509,015 B1	01/21/2003	Salfeld <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
DB	A4	Asadullah <i>et al.</i> "A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor α overexpression." <i>Br. J. Dermatol.</i> 1999 Jul;141(1):94-102			
	A5	Chaudhari <i>et al.</i> "Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial." <i>Lancet.</i> 2001 Jun 9;357(9271):1842-7			
	A6	Davison <i>et al.</i> "Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy." <i>Br. J. Dermatol.</i> 2002 Oct;147(4):831-2			
	A7	Elewski "Infliximab for the treatment of severe pustular psoriasis." <i>J. Am. Acad. Dermatol.</i> 2002 Nov;47(5):796-7			
	A8	Iyer <i>et al.</i> "Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy." <i>Br. J. Dermatol.</i> 2002 Jan;146(1):118-21			
	A9	Kamarashev <i>et al.</i> "Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept." <i>Dermatology.</i> 2002;205(2):213-6			
	A10	Kirby <i>et al.</i> "Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate." <i>Clin. Exp. Dermatol.</i> 2001 Jan;26(1):27-9			
	A11	Mackiewicz <i>et al.</i> "Dual effects of caspase-1, interleukin-1 β , tumour necrosis factor- α and nerve growth factor receptor in inflammatory myopathies." <i>Clin. Exp. Rheumatol.</i> 2003 Jan-Feb;21(1):41-8			
	A12	Mang <i>et al.</i> "Response of severe psoriasis to infliximab." <i>Dermatology.</i> 2002;204(2):156-7			
DB	A13	Mease <i>et al.</i> "Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial." <i>Lancet.</i> 2000 Jul 29;356(9227):385-90			
Examiner Signature		/David Blanchard/			08/14/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/622205	
			Filing Date	July 18, 2003	
			First Named Inventor	Subhashis Banerjee	
			Art Unit	1641	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	BPI-195

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number-Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
DB	B1	Moretti <i>et al.</i> "Vitiligo and epidermal microenvironment: possible involvement of keratinocyte-derived cytokines." <i>Arch. Dermatol.</i> 2002 Feb;138(2):273-4			
	B2	Moretti <i>et al.</i> "New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions." <i>Pigment Cell Res.</i> 2002 Apr;15(2):87-92			
	B3	Murota H <i>et al.</i> "Disruption of tumor necrosis factor receptor p55 impairs collagen turnover in experimentally induced sclerodermic skin fibroblasts." <i>Arthritis Rheum.</i> 2003 Apr;48(4):1117-25			
	B4	Newland <i>et al.</i> "Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type." <i>Int. J. Dermatol.</i> 2002 Jul;41(7):449-52			
	B5	O'Quinn <i>et al.</i> "The effectiveness of tumor necrosis factor α antibody (infliximab) in treating recalcitrant psoriasis: A report of 2 cases." <i>Arch. Dermatol.</i> 2002 May;138(5):644-8			
	B6	Reuss-Borst <i>et al.</i> "Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease." <i>Br. J. Haematol.</i> 1993 Jun;84(2):356-8			
	B7	Russell-Jones <i>et al.</i> "High-dose interferon and the U.K. guidelines for cutaneous melanoma." <i>Br. J. Dermatol.</i> 2002 Oct;147(4):832-4			
	B8	Schopf <i>et al.</i> "Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor α , infliximab." <i>J. Am. Acad. Dermatol.</i> 2002 Jun;46(6):886-91			
	B9	Takematsu <i>et al.</i> "Absence of tumor necrosis factor- α in suction blister fluids and stratum corneum from patients with psoriasis." <i>Arch. Dermatol. Res.</i> 1989;281(6):398-400			
DB	B10	Tutuncu Z <i>et al.</i> "Anti-TNF therapy for other inflammatory conditions." <i>Clin. Exp. Rheumatol.</i> 2002 Nov-Dec;20(6 Suppl 28):S146-51			
Examiner Signature	Date Considered	/David Blanchard/ 08/14/2006			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO		Complete if Known	
INFORMATION DISCLOSURE		Application Number	10/622205
		Filing Date	July 18, 2003

				First Named Inventor	Subhashis Banerjee
				Art Unit	1641
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	BPI-195

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
DB	C1	WO 02/100330 A2	12/19/2002	Abbott Laboratories		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Examiner Signature		Date Considered /David Blanchard/ 08/14/2006	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.